Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial.
Therapy with individual 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ( statins ) has been shown conclusively to diminish coronary event rates and mortality in both primary and secondary prevention . To date , scant attention has been paid to whether initiation of such regimens in the hospital phase of acute coronary syndromes might confer cardioprotective benefits . The purpose of this study was to determine the safety and tolerability of early initiation of statin therapy in patients with acute coronary syndromes . In this r and omised , double-blind , three-month , pilot study , 100 patients with acute myocardial infa rct ion or unstable angina and low-density lipoprotein cholesterol > 3.5 mmol/l were r and omly assigned to pravastatin 40 mg daily or placebo initiated within 48 hours of hospital admission . Pravastatin proved safe and well tolerated in these patients , who were well matched at baseline . No statistically significant differences in death , MI and drug-related adverse events were observed in the pravastatin group compared with control subjects . This pilot study shows that therapy with pravastatin early after an acute coronary event is safe and well tolerated . Larger , long-term studies are needed to confirm these findings
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .